10.41
3.07%
0.31
Y Mabs Therapeutics Inc Azioni (YMAB) Dati Finanziari
Conto economico
Trimestrale
*Tutti i numeri sono espressi in milioni
Data di fine periodo | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
Durata del periodo | 3 mesi | 3 mesi | 3 mesi | 3 mesi | 3 mesi |
Revenues |
14.69%
19.93
|
23.36 | 20.45 | 20.75 | 20.25 |
Cost Of Revenue |
2.84%
2.097
|
2.039 | 2.595 | 4.649 | 2.083 |
Gross Profit |
16.37%
17.83
|
21.32 | 17.86 | 16.10 | 18.17 |
Operating Expenses
|
0.89%
24.74
|
24.52 | 25.61 | 23.32 | 25.67 |
Benefits Costs and Expenses |
9.29%
26.40
|
24.16 | 28.01 | 26.87 | 26.64 |
Costs And Expenses |
1.04%
26.84
|
26.56 | 28.20 | 27.97 | 27.75 |
Operating Income/Loss |
115.94%
-6.908
|
-3.199 | -7.749 | -7.223 | -7.501 |
Income/Loss From Continuing Operations Before Tax |
715.76%
-6.469
|
-0.793 | -7.56 | -6.123 | -6.39 |
Income Tax Expense/Benefit, Current |
17.95%
0.16
|
0.195 | 0.187 | 0.179 | - |
Income Tax Expense/Benefit |
17.95%
0.16
|
0.195 | 0.187 | 0.179 | - |
Income/Loss From Continuing Operations After Tax |
570.95%
-6.629
|
-0.988 | -7.747 | -6.302 | -6.39 |
Net Income/Loss
|
570.95%
-6.629
|
-0.988 | -7.747 | -6.302 | -6.39 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
712.19K%
43.78
|
-0.00615 | 43.62 | 43.66 | 43.67 |
Diluted Average Shares |
712.19K%
43.78
|
-0.00615 | 43.62 | 43.66 | 43.67 |
Basic Earnings Per Share |
650.00%
-0.15
|
-0.02 | -0.18 | -0.14 | -0.15 |
Diluted Earnings Per Share |
650.00%
-0.15
|
-0.02 | -0.18 | -0.14 | -0.15 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):